Altimmune raises ~$211M in public offering to fund MASH Phase 3 trial

On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).